Peter J. Goebell, MD, PhD, is Associate Professor in the Department of Urology at the University Comprehensive Cancer Center (UCC) in Erlangen, Germany. He is a graduate of the Medical School at the Heinrich-Heine University in Düsseldorf, Germany, where he also startedcompleted his surgical and, later, his urological training. Following a Research Fellowship at the University of Southern California, Los Angeles, USA, he completed his urological training at the Comprehensive Cancer Center, University of Essen, Germany, where he also received his board approval in 2005.
Professor Goebell’s research focuses since his thesis is on molecular alterations during the development and progression of bladder cancer and has formed the basis for most of the current clinical science projects he is involved in, either within clinical trials or interdisciplinary networks.
Professor Goebell is a specialist in genito-urinary cancer with a focus on bladder cancer. He has extensive experience in working in clinic-academic networks. He has contributed to various meta-analyses projects and participated actively in the consensus group for the German S3-Guidelines on bladder cancer. In addition to the many clinical trials, he is involved in as a Principal Iinvestigator, his research interests includes activities as part ofof the International Bladder Cancer Network (IBCN) – an international, interdisciplinary consortium of highly recognised clinicians, scientists, and basic researchers from over 50 high-volume centres working on molecular alterations and their clinical application in bladder cancer (www.ibcnweb.net). Following his long term as the General Secretary of this network, Professor Goebell has been the president of this network since 2012, after having previously served as the General Secretary for many years.
EM-77762 - Date of Preparation: October 2021